News
First insight into the revision of the EU pharma legislation 27-04-2021
ESIP responds to the evaluation roadmap-inception impact assessment
On 30 March the Commission launched the first stage of consultations with stakeholders towards the revision of the general pharmaceutical legislation, namely Directive 2001/83/EC1 and Regulation (EC) No 726/2004. ESIP submitted its first response to the evaluation roadmap-inception impact assessment touching upon several elements identified by the Commission to feed into future policy actions.
Promoting active & healthy ageing across the lifespan 20-04-2021
ESIP responds to the Public Consultation on the Green Paper on Ageing
Social protection schemes in the EU are under strain as ageing increases demand for medical and long-term care (LTC) and old-age spending. In this context, ESIP provides its recommendations touching upon all branches of social security on how to tackle demographic change while fostering active and healthy ageing.
3rd EMA-payer meeting on 12 March 2021 17-03-2021
Payers and EMA discussed evidence generation along the life-cycle of medicines
On 12 March, representatives from the European Social Insurance Platform (ESIP), the payer platform Medicines Evaluation Committee (MEDEV), the International Association of Mutual Benefit Societies (AIM) and the European Medicines Agency (EMA) met for the third time to further explore synergies and foster mutual understanding and cooperation on evidence generation, with the aim of better aligning evidence requirements for the different decision-making processes. On this occasion the focus was on evidence generation along the life-cycle of medicinal products.
More proposals on managing & preventing shortages 25-02-2021
New ESIP Paper on shortages of Medical Devices and PPE
In light of the lessons learned from COVID-19, ESIP welcomes and supports the reinforced European commitment to secure continuous supply of medicines, medical devices (MD) and personal protective equipment (PPE). In our recently adopted position paper we outline proposals for securing supply of MD and PPE, building upon our position on medicines shortages and taking stock of the measures specific to MD in the legislative proposals on Building an EU Health Union.
